Anzeige
Mehr »
Login
Dienstag, 01.04.2025 Börsentäglich über 12.000 News von 695 internationalen Medien
Kurs-Explosion voraus?: Diese kaum bekannte Aktie bohrt jetzt im Hotspot - und du erfährst es als Erster!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40G78 | ISIN: US04522R3093 | Ticker-Symbol: N/A
NASDAQ
18.07.24
21:59 Uhr
0,600 US-Dollar
0,000
0,00 %
1-Jahres-Chart  (nicht börsennotiert)
ASLAN PHARMACEUTICALS LTD ADR Chart 1 Jahr

Aktuelle News zur ASLAN PHARMACEUTICALS

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17.07.24ASLAN PHARMACEUTICALS LIMITED: ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation287Following a thorough review of all strategic alternatives, ASLAN Pharmaceuticals Pte Ltd, the sole operating subsidiary of ASLAN Pharmaceuticals, has filed for voluntary liquidation Quantuma (Singapore)...
► Artikel lesen
15.07.24ASLAN PHARMACEUTICALS LIMITED: ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal184SAN MATEO, Calif. and SINGAPORE, July 15, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals ("ASLAN" or the "Company", Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing...
► Artikel lesen
14.06.24ASLAN PHARMACEUTICALS LIMITED: ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change307SAN MATEO, Calif. and SINGAPORE, June 14, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals ("ASLAN" or the "Company", Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing...
► Artikel lesen
02.05.24ASLAN PHARMACEUTICALS LIMITED: ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics330New research collaboration will explore the differentiation of eblasakimab's mechanism of action versus biologic therapies for atopic dermatitis (AD), dupilumab and lebrikizumab.The findings will...
► Artikel lesen
22.04.24ASLAN PHARMACEUTICALS LIMITED: ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients226Interim readout of 22 patients shows unprecedented efficacy data compared to prior atopic dermatitis (AD) studies with biologics: 60.0% of dupilumab-experienced AD patients treated with 400mg eblasakimab...
► Artikel lesen
19.04.24ASLAN PHARMACEUTICALS LIMITED: ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice358SAN MATEO, Calif. and SINGAPORE, April 19, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments...
► Artikel lesen
ASLAN PHARMACEUTICALS Aktie jetzt für 0€ handeln
12.04.24ASLAN PHARMACEUTICALS LIMITED: ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update321In a preliminary review of blinded data from the ongoing TREK-DX study, 45% (10/22) of patients achieved at least a 90% reduction in their EASI score (EASI-90) after 16 weeks. 56% (5/9) of patients...
► Artikel lesen
7 Nachrichten in den letzten 12 Monaten